Anika Therapeutics Inc.ANIK is a Biomedicine company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ANIK's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Anika Therapeutics could be a solid choice for investors.
Current Quarter Estimates for ANIK
In the past 30 days, 2 estimates have gone higher for Anika Therapeutics while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 25 cents a share 30 days ago, to 29 cents today, a move of 16%.
Current Year Estimates for ANIK
Meanwhile, Anika Therapeutics' current year figures are also looking quite promising, with 3 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.58 per share 30 days ago to $1.77 per share today, an increase of 12%.
The stock has also started to move higher lately, adding 15% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.